



Matteo Rosellini

Nationality: Italian **Date of birth:** 06/10/1992 **Gender:** Male **Email address:** matteorosellini92@gmail.com

Email address: matteo.rosellini@ta.omceo.it

WORK EXPERIENCE

Medical Oncologist, Medical Doctor

IRCCS Azienda Ospedaliero-Universitaria di Bologna [20/11/2024 – Current]

Address: Via Albertoni 15, 40138 Bologna (Italy)

Working as a **Medical Oncologist focused on the management of GU cancer patients (kidney cancer, prostate cancer, urothelial cancer and testicular malignancies)** at IRCCS Azienda Ospedaliero-Universitaria di Bologna. Actively involved in Oncological Research, attending a **PhD in Oncology, Hematology and Pathology** of the ALMA Mater Studiorum - Università di Bologna with a project entitled "The role of molecular and histopathological features as prognostic or predictive biomarkers for immunotherapy in renal cell carcinoma" and working in the Research Lab led by Prof. Francesco Massari. Actively involved in inpatient and Day Service Activities at Oncology Unit of the IRCCS AOUBO.

Oncology Resident, Medical Doctor

IRCCS Azienda Ospedaliero-Universitaria di Bologna [01/11/2019 – 31/10/2024]

City: Bologna | **Country:** Italy

Worked as Oncology Resident at the Medical Oncology Unit, IRCCS Azienda Ospedaliero-universitaria di Bologna, Policlinico Sant'Orsola-Malpighi (Via Albertoni 15, 40138, Bologna, Italy), actively involved in inpatient and Day Service activities in the Oncology Unit. In particular, I focused my research activity on genitourinary cancers (kidney cancer, prostate cancer, urothelial cancer and testicular cancer) working in the Research Lab led by Prof. Francesco Massari. Finished my Residency with the final grade of 110/110 cum laude, with the thesis entitled "**Exploring the prognostic value of chromosome 3p gene mutations in patients with metastatic renal cell carcinoma treated with first line immune-based combinations or tyrosine-kinase inhibitors**".

EDUCATION AND TRAINING

PhD Student in "PhD Oncology, Ematology and Pathology (40th cycle)"

ALMA Mater Studiorum - Università di Bologna [01/11/2024 – Current]

City: Bologna | **Country:** Italy | **Website:** <https://www.unibo.it/en/study/phd-professional-masters-specialisation-schools-and-other-programmes/phd/2024-2025/oncology-hematology-and-pathology> | **Field(s) of study:** Medical Oncology | **Level in EQF:** EQF level 8

Medical Doctor Specialised in Medical Oncology

ALMA Mater Studiorum - Università di Bologna [01/11/2019 – 31/10/2024]

Address: Via Albertoni 15, Bologna, Italy, 40138 Bologna (Italy) | **Website:** www.unibo.it | **Field(s) of study:** Medical Oncology | **Final grade:** 110/110 cum laude | **Level in EQF:** EQF level 8 | **Thesis:** Exploring the prognostic value of chromosome 3p gene mutations in patients with metastatic renal cell carcinoma treated with first line immune-based combinations or tyrosine-kinase inhibitors

Advanced Cardiovascular Life Support (ACLS) Provider

American Heart Association [08/05/2024 – Current]

City: Bologna | **Country:** Italy | **Website:** www.international.heart.org

Participated in the ESMO Preceptorship on Metastatic Bladder and Kidney Cancer - Multidisciplinary management, standards of care, therapeutic targets and future perspectives

ESMO [03/04/2024 – 04/04/2024]

City: Lugano | Country: Switzerland | Website: www.esmo.org

Qualification for the ICH GOOD CLINICAL PRACTICE E6 (R2)

The Global Health Network [24/10/2023 – Current]

City: Bologna | Country: Italy

Qualification for the Medical Profession

Università degli Studi di Siena [07/2019]

Country: Italy | Level in EQF: EQF level 7

Master Bachelor Degree in Medicine and Surgery

Università degli Studi di Siena [10/2012 – 12/2018]

Address: Facoltà di Medicina e Chirurgia Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, 53100 Siena (Italy) | Final grade: 110/110 con lode | Level in EQF: EQF level 7 | Thesis: "Retinoblastoma neonatale: chemioterapia sistemica comparata a terapia bridge a chemioterapia intra-arteriosa."

High school leaving qualification in classical studies

Liceo Classico "Tito Livio" [2006 – 2011]

Address: 74015 Martina Franca (TA) (Italy) | Level in EQF: EQF level 4

LANGUAGE SKILLS

Mother tongue(s): Italian

Other language(s):

Inglese

LISTENING B2 READING B2 WRITING B2

SPOKEN PRODUCTION B2 SPOKEN INTERACTION B2

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

DIGITAL SKILLS

Padronanza del Pacchetto Office (Word Excel PowerPoint ecc) / Gestione autonoma della posta e-mail / Microsoft Office / GoogleChrome / Social Network / Sistemi operativi: ottima padronanza di iOS, macOS, Android e Windows / Gmail / BioRender / REDCap

PUBLICATIONS

[2021]
Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M, Storti N, Battelli N, Montironi R, Massari F. "Treating Prostate Cancer by Antibody-Drug Conjugates." *Int J Mol Sci.* 2021 Feb 4;22(4):1551. doi: 10.3390/ijms22041551.

doi: 10.3390/ijms22041551

[2021]
Marchetti A, Rosellini M, Rizzo A, Mollica V, Battelli N, Massari F, Santoni M. "An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma." *Expert Opin Pharmacother.* 2021 Dec;22(17): 2323-2336. doi: 10.1080/14656566.2021.1959548. Epub 2021 Aug 18.

doi: 10.1080/14656566.2021.1959548

[2021]

Mollica V, Rizzo A, Rosellini M, Marchetti A, Ricci AD, Cimagli A, Scarpelli M, Bonucci C, Andrini E, Errani C, Santoni M, Montironi R, Massari F. "Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art." *Cancers (Basel)*. 2021 Feb 1;13(3):546. doi: 10.3390/cancers13030546.

doi: 10.3390/cancers13030546.

[2021]

Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, Cimagli A, Santoni M, Fiorentino M, Montironi R, Massari F. "The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?" *Int J Mol Sci*. 2021 Jun 9;22(12):6237. doi: 10.3390/ijms22126237

doi: 10.3390/ijms22126237.

[2021]

Rizzo A, Rosellini M, Marchetti A, Mollica V, Massari F. "Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence." *Immunotherapy*. 2021 Jun;13(8):685-692. doi: 10.2217/imt-2020-0323. Epub 2021 Apr 7.

doi: 10.2217/imt-2020-0323

[2021]

Rizzo A, Mollica V, Santoni M, Ricci AD, Rosellini M, Marchetti A, Montironi R, Ardizzoni A, Massari F. "Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials." *Eur Urol Focus*. 2021 Mar 10;S2405-4569(21)00058-4. doi: 10.1016/j.euf.2021.03.001.

doi: 10.1016/j.euf.2021.03.001.

[2021]

Rizzo A, Mollica V, Giunchi F, Dall'Olio FG, Rosellini M, Marchetti A, Franceschini T, Schiavina R, Brunocilla E, Fiorentino M, Ardizzoni A, Massari F. "Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience." *Pathol Res Pract*. 2021 Apr;220:153410. doi: 10.1016/j.prp.2021.153410

doi: 10.1016/j.prp.2021.153410

[2021]

Rizzo A, Santoni M, Mollica V, Logullo F, Rosellini M, Marchetti A, Faloppi L, Battelli N, Massari F. "Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study." *Expert Opin Drug Metab Toxicol*. 2021 Dec;17(12):1455-1466. doi: 10.1080/17425255.2021.2029405.

doi: 10.1080/17425255.2021.2029405.

[2021]

Massari F, Rizzo A, Mollica V, Rosellini M, Marchetti A, Ardizzoni A, Santoni M. "Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials." *Eur J Cancer*. 2021 Sep;154:120-127. doi: 10.1016/j.ejca.2021.06.015.

doi: 10.1016/j.ejca.2021.06.015

[2021]

Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Ricci AD, Grilli G, Greco A, Montironi R, Ardizzoni A, Massari F. "Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis." *Immunotherapy*. 2021 Jun;13(9):783-793. doi: 10.2217/imt-2021-0005.

doi: 10.2217/imt-2021-0005

[2021]

Rizzo A, Mollica V, Rosellini M, Marchetti A, Ricci AD, Fiorentino M, Battelli N, Santoni M, Massari F. "Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials." Pathol Res Pract. 2021 Jun; 222:153440. doi: 10.1016/j.prp.2021.153440.

doi: 10.1016/j.prp.2021.153440.

[2021]

Rizzo A, Mollica V, Dall'Olio FG, Ricci AD, Maggio I, Marchetti A, Rosellini M, Santoni M, Ardizzoni A, Massari F. "Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review." Future Oncol. 2021 Jul;17(20):2671-2681. doi: 10.2217/fon-2021-0069.

doi: 10.2217/fon-2021-0069

[2021]

Mollica V, Marchetti A, Rosellini M, Nuvola G, Rizzo A, Santoni M, Cimadamore A, Montironi R, Massari F. "An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT." Int J Mol Sci. 2021 Dec 16;22(24):13519. doi: 10.3390/ijms222413519.

doi: 10.3390/ijms222413519

[2022]

Mollica V, Santoni M, Matrana MR, Basso U, De Giorgi U, Rizzo A, Maruzzo M, Marchetti A, Rosellini M, Bleve S, Maslov D, Tawagi K, Philon E, Blake Z, Massari F. "Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma." Target Oncol. 2022 Jan;17(1):61-68. doi: 10.1007/s11523-021-00861-y.

doi: 10.1007/s11523-021-00861-y

[2022]

Santoni M, Rizzo A, Mollica V, Rosellini M, Marchetti A, Fragomeno B, Battelli N, Massari F. "Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis." Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1): 45-51. doi: 10.1080/14737167.2021.1937130.

doi: 10.1080/14737167.2021.1937130.

[2022]

Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Massari F. "Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials." Future Oncol. 2022 Feb;18(5):625-634. doi: 10.2217/fon-2021-0888.

doi: 10.2217/fon-2021-0888

[2022]

Nigro MC, Mollica V, Marchetti A, Cheng M, Rosellini M, Montironi R, Cheng L, Massari F. "Current androgen receptor antagonists under investigation for resistant prostate cancer." Expert Rev Anticancer Ther. 2022 Feb;22(2):191-202. doi: 10.1080/14737140.2022.2020651.

doi: 10.1080/14737140.2022.2020651

[2022]

Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, Marchetti A, Battelli N, Massari F. "The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study." Crit Rev Oncol Hematol. 2022 Feb;170:103596. doi: 10.1016/j.critrevonc.2022.103596.

doi: 10.1016/j.critrevonc.2022.103596

[2022]

Marchetti A, Rosellini M, Nuvola G, Tassinari E, Mollica V, Rizzo A, Santoni M, Cimadamore A, Farolfi A, Montironi R, Fanti S, Massari F. "PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-

Resistant Prostate Cancer: What's Now, What's New, and What's Coming?" Cancers (Basel). 2022 Feb 11;14(4): 907.

doi: 10.3390/cancers14040907.

[2022]

Mollica V, Nuvola G, Tassinari E, Nigro MC, Marchetti A, Rosellini M, Rizzo A, Errani C, Massari F. "Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw." Curr. Oncol. 2022, 29, 1709–1722. <https://doi.org/10.3390/curroncol29030142>

<https://doi.org/10.3390/curroncol29030142>

[2022]

Tassinari E, Mollica V, Nuvola G, Marchetti A, Rosellini M, Massari F. "Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy". Cancer Manag Res. 2022 Jun 13;14:1945-1960. doi: 10.2147/CMAR.S287904

doi: 10.2147/CMAR.S287904

[2022]

Rizzo A, Mollica V, Marchetti A, Nuvola G, Rosellini M, Tassinari E, Molina-Cerrillo J, Myint ZW, Buchler T, Monteiro FSM, Grande E, Santoni M, Massari F. "Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study." Cancers (Basel). 2022 Aug 26;14(17):4142. doi: 10.3390/cancers14174142

doi: 10.3390/cancers14174142

[2022]

Mollica V, Massari F, Andrini E, Rosellini M, Marchetti A, Nuvola G, Tassinari E, Lamberti G, Campana D. "Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis." Curr Oncol. 2022 Aug 18;29(8):5846-5854. doi: 10.3390/curroncol29080461

doi: 10.3390/curroncol29080461

[2022]

Marchese PV, Mollica V, De Biase D, Giunchi F, Tassinari E, Marchetti A, Rosellini M, Nuvola G, Maloberti T, Fiorentino M, Massari F. "A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy." Pathol Res Pract. 2022 Aug;236:153983. doi: 10.1016/j.prp.2022.153983.

doi: 10.1016/j.prp.2022.153983

[2022]

Andrini E, Federico AD, Sisi M, Rosellini M, Palladini A, Lamberti G, Giglio A, Gelsomino F. "Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies." Immunotherapy. 2022 Nov; 14(16):1329-1340. doi: 10.2217/imt-2022-0060.

doi: 10.2217/imt-2022-0060.

[2022]

Marchese PV, Mollica V, Tassinari E, De Biase D, Giunchi F, Marchetti A, Rosellini M, Fiorentino M, Massari F. "Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers." Expert Rev Mol Diagn. 2022 Dec 12:1-12. doi: 10.1080/14737159.2022.2154148.

doi: 10.1080/14737159.2022.2154148.

[2022]

Rosellini M, Marchetti A, Tassinari E, Nuvola G, Rizzo A, Santoni M, Mollica V, Massari F. "Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer". *Expert Rev. Precis. Med. Drug Dev.* 2022 Dec. doi: 10.1080/23808993.2022.2156786
doi: 10.1080/23808993.2022.2156786

[2023]
Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F. "Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma." *Nat Rev Urol.* 2023 Mar;20(3):133-157. doi: 10.1038/s41585-022-00676-0.
doi: 10.1038/s41585-022-00676-0.

[2023]
Marchetti A, Tassinari E, Rosellini M, Rizzo A, Massari F, Mollica V. "Prostate cancer and novel pharmacological treatment options-what's new for 2022?" *Expert Rev Clin Pharmacol.* 2023 Mar;16(3):231-244. doi: 10.1080/17512433.2023.2181783
doi: 10.1080/17512433.2023.2181783

[2023]
Nuvola G, Santoni M, Rizzo M, Rosellini M, Mollica V, Rizzo A, Marchetti A, Battelli N, Massari F. "Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer." *Expert Rev Anticancer Ther.* 2023 Jun;23(6):593-600. doi: 10.1080/14737140.2023.2207827.
doi: 10.1080/14737140.2023.2207827

[2023]
Rizzo A, Nuvola G, Palmiotti G, Ahcene-Djaballah S, Mollica V, Rosellini M, Marchetti A, Nigro MC, Tassinari E, Macrini S, Massari F. "Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis." *Immunotherapy.* 2023 Feb;15(2):117-126. doi: 10.2217/imt-2022-0023.
doi: 10.2217/imt-2022-0023

[2023]
Rizzo A, Mollica V, Tateo V, Tassinari E, Marchetti A, Rosellini M, De Luca R, Santoni M, Massari F. "Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study." *Cancer Immunol Immunother.* 2023 Jun;72(6):1381-1394. doi: 10.1007/s00262-023-03366-x.
doi: 10.1007/s00262-023-03366-x

[2023]
Rosellini M, Tassinari E, Marchetti A, Tateo V, Nuvola G, Rizzo A, Massari F, Mollica V. "An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma." *Expert Opin Drug Saf.* 2023 Apr;22(4):279-291. doi: 10.1080/14740338.2023.2203486.
doi: 10.1080/14740338.2023.2203486

[2023]
Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A, Tassinari E, Monteiro FSM, Soares A, Molina-Cerrillo J, Grande E, Battelli N, Massari F. "Complete remissions following immunotherapy or immunoooncology combinations in cancer patients: the MOUSEION-03 meta-analysis." *Cancer Immunol Immunother.* 2023 Jun;72(6):1365-1379. doi: 10.1007/s00262-022-03349-4.
doi: 10.1007/s00262-022-03349-4

[2023]

Mollica V, Rizzo A, Marchetti A, Tateo V, Tassinari E, Rosellini M, Massafra R, Santoni M, Massari F. "The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study." *Clin Exp Med.* 2023 Aug 3. doi: 10.1007/s10238-023-01159-1. doi: 10.1007/s10238-023-01159-1

[2023]

Rosellini M, Tassinari E, Marchetti A, Mollica V, Massari F. "Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial." *Eur Urol.* 2023 Sep 28:S0302-2838(23)03136-6. doi: 10.1016/j.eururo.2023.09.011. doi: 10.1016/j.eururo.2023.09.011

[2023]

Conci N, Tassinari E, Tateo V, Rosellini M, Marchetti A, Ricci C, Chessa F, Santoni M, Grande E, Mollica V, Massari F. "How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?" *Mol Diagn Ther.* 2023 Oct 24. doi: 10.1007/s40291-023-00679-6. doi: 10.1007/s40291-023-00679-6

[2024]

Mollica V, Tassinari E, Santoni M, Marchese PV, Giunchi F, Maloberti T, Tateo V, Ricci C, Rosellini M, Marchetti A, Fiorentino M, Biase D, Massari F. "TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab." *Pathol Res Pract.* 2024 Jan;253:155008. doi: 10.1016/j.prp.2023.155008. doi: 10.1016/j.prp.2023.155008.

[2024]

Rosellini M, Mollica V, Marchetti A, Coluccelli S, Giunchi F, Tassinari E, Ricci C, Fiorentino M, Tallini G, De Biase D, Massari F. "Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis." *Pathol Res Pract.* 2024 Jan 17;254:155142. doi: 10.1016/j.prp.2024.155142. doi: 10.1016/j.prp.2024.155142.

[2024]

Tassinari E, Rosellini M, Marchetti A, Mollica V, Massari F. "What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?" *Expert Opin Drug Metab Toxicol.* 2024 Feb 1:1-4. doi: 10.1080/17425255.2024.2314059. doi: 10.1080/17425255.2024.2314059

[2024]

Maffezzoli M, Santoni M, Mazzaschi G, Rodella S, Lai E, Maruzzo M, Basso U, Bimbatti D, Iacovelli R, Anghelone A, Fiala O, Rebuzzi SE, Fornarini G, Lolli C, Massari F, Rosellini M, Mollica V, Nasso C, Acunzo A, Silini EM, Quaini F, De Filippo M, Brunelli M, Banna GL, Rescigno P, Signori A, Buti S. "External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations." *Clin Exp Metastasis.* 2024;41(2):117-129. doi: 10.1007/s10585-024-10266-6

[2024]

Mollica V, Rosellini M, Brocchi S, Galuppi F, Paccapelo A, Tateo V, Marchetti A, Tassinari E, Mantuano F, Santoni M, Massari F. "Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma." *Expert Rev Precis Med Drug Dev.* 2024;9:1, 17-24.
doi: 10.1080/23808993.2024.2330422

[2024]

Massari F, Santoni M, Takeshita H, et al. "Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study." *Cancer Immunol Immunother.* 2024;73(6):106. Published 2024 Apr 18.

*Full list of the Authors: Massari F, Santoni M, Takeshita H, Okada Y, Tapia JC, Basso U, Maruzzo M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Gandur N, Lam ET, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Kemp R, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Kürönya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Mennitto A, Nogueira L, de Carvalho Fernandes R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Kopp RM, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchhorn D, Santini D, Bamias A, Bissoni R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Marchetti A, **Rosellini M**, Sorgentoni G, Battelli N, Buti S, Porta C, Bellmunt J.*

doi: 10.1007/s00262-024-03682-w

[2024]

Mollica V, Marchetti A, Fraccascia N, Nanni C, Tabacchi E, Malizia C, Argalia G, Rosellini M, Tassinari E, Paccapelo A, Fanti S, Massari F. "A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience." *ESMO Open.* 2024 May 7;9(5):103448.
doi: 10.1016/j.esmoop.2024.103448

[2024]

Massari F, Rosellini M, Mollica V. "Overall survival with adjuvant pembrolizumab in renal cell carcinoma - the shock of the lightning." *Nat Rev Urol.* 2024 May 17. Epub ahead of print.
doi: 10.1038/s41585-024-00896-6

[2024]

Rosellini M, Marchetti A, Tassinari E, Mollica V, Massari F, Santoni M. "Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?" *Expert Opin Biol Ther.* 2024 Jun;24(6):411-414
doi: 10.1080/14712598.2024.2369190

[2024]

De Giglio A, Leonetti A, Comito F, Filippini DM, Mollica V, Rihawi K, Peroni M, Mazzaschi G, Ricciotti I, Carosi F, Marchetti A, Rosellini M, Gagliano A, Favorito V, Nobili E, Gelsomino F, Melotti B, Marchese PV, Sperandi F, Di Federico A, Buti S, Perrone F, Massari F, Pantaleo MA, Tiseo M, Ardizzoni A. "Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy." *Cancer Immunol Immunother.* 2024 Oct 3;73(12):246
doi: 10.1007/s00262-024-03836-w.

[2024]

Compagno S, Casadio C, Galvani L, Rosellini M, Marchetti A, Tassinari E, Piazza P, Mottaran A, Santoni M, Schiavina R, Massari F, Mollica V. "Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives." J Clin Med. 2024 Sep 26;13(19):5738. doi: 10.3390/jcm13195738.

DRIVING LICENCE

Driving Licence: B

CONFERENCES AND SEMINARS

[23/01/2020 – 23/01/2020] Bologna

Thoracic Cancer Highlights: Best of Year 2019

[15/10/2020 – 15/10/2020] Online

Blended learning for immuno-oncologists

[01/12/2021 – 01/12/2021] Online

Nivolution Plus 2021 - RCC

[05/12/2021 – 13/02/2022] Online

Blended learning for immuno-oncologists 2.0

[03/03/2022 – 04/03/2022] Verbania

Young Onco-GU 2022

[27/05/2022] Bologna

Focus on nmCRPC

[07/06/2022] Bologna

m-BRaCe - The future treatment for patient with mCRPC and BRCA mutations

[12/06/2022 – 13/06/2022] Online

COMU (Panel of Italian Medical Oncologists) summarize and comment on Chicago 2022 - The evolution of knowledge in Medical Oncology

[21/09/2022] Genova

YOUNG TO YOUNG 2022 - L'oncologia di domani

[23/09/2022 – 24/09/2022] Bologna

Testicular Cancer - State of the art and future perspective

[20/04/2023 – 21/04/2023] Castelfranco Veneto (TV)

Advanced Uro-Oncology Days

[28/06/2023 – 28/06/2023] Bologna

L'algoritmo terapeutico del carcinoma renale metastatico

Discussion between experts, during which I shown the presentation entitled "**Combinazione IO-TKI e IO-IO in prima linea di trattamento del carcinoma renale**", regarding the available first-line options for metastatic renal cell carcinoma therapy.

[06/10/2023 – 06/10/2023] Bologna

Il percorso del test BRCA per il paziente mCRPC

[02/11/2023 – 05/11/2023] Marsiglia

15th European Multidisciplinary Congress on Urological Cancers (EMUC23)

During this Congress, I presented the abstract entitled "**P153. A hypothesis generating analysis of the role of chromosome 3p-related genes as predictors for immunocombinations in metastatic renal cell carcinoma (mRCC)**", which had been accepted for the **Poster Session**.

[10/11/2023 – 12/11/2023] Roma

XXV Congresso Nazionale AIOM

During this Congress, I presented the abstract entitled "**A46. Evaluation of response to pembrolizumab plus axitinib with tumor growth rate (TGR) in patients (pts) with metastatic renal cell carcinoma (mRCC)**", which had been accepted for the **Poster Session**.

[06/12/2023 – 08/12/2023] Ginevra

ESMO Immuno-Oncology Congress 2023

During this Congress, I presented the abstract entitled "**#193. Chromosome 3p-related gene alterations (GA) as biomarkers for immunocombinations in metastatic renal cell carcinoma (mRCC): a hypothesis-generating analysis**", which had been accepted for the **Poster Session**.

[14/12/2023 – 16/12/2023] Genova

GRANDANGOLO 2023. A year of Medical Oncology.

[03/04/2024 – 04/04/2024] Lugano, Switzerland

ESMO Preceptorship on Metastatic Bladder and Kidney Cancer, 3-4 April 2024, Lugano, Switzerland

During this ESMO Preceptorship, I was selected to present a clinical case entitled "**Severe combined cardiac and neuromuscular toxicity from 1st line immune-based combination in mRCC: a case report**" during the Session 6 of the event ("Focus on toxicity and duration of therapy").

[17/10/2024 – 17/10/2024] Bologna

Wiki Prostate Cases

[29/11/2024 – 29/11/2024] Bologna

Il PERCORSO del TEST BRCA per il paziente mCRPC un anno dopo

[11/2019 – Current]

Subinvestigator in PRIORI study

"Studio per la valutazione di marcatori molecolari estratti da DNA predittivi degli outcomes clinici e di risposta a terapia sistemica nei pazienti con tumore del rene".

Code: 321/2019/Sper/AOUBo

[03/2022 – Current]

Subinvestigator in APACHE-I study

[03/2022 – Current]

Subinvestigator in MeetURO-18 TME-I study

[03/2022 – Current]

Subinvestigator in ECHOS study

[03/2022 – Current]

Subinvestigator in MeetURO-23 (I-RARE) study

[12/2022 – Current]

Subinvestigator in PROCURO study

"Studio per la valutazione di marcatori molecolari estratti da DNA PRedittivi degli Outcomes Clinici e di risposta a terapia sistemica nei pazienti con tumore dell'UROtelio".

[10/2022 – Current]

Subinvestigator in SCOPRO study

"Studio per la valutazione di marcatori molecolari estratti da DNA predittivi degli outCOMes clinici e di risposta a terapia sistemica nei pazienti con tumore PROstatico".

[12/2022 – Current]

Subinvestigator in PARARE study

[11/2023 – Current]

Subinvestigator in SIGN-RCC study

[13/11/2023 – Current]

Subinvestigator in phase III LITESPARK-022 randomized clinical trial (NCT05239728)

"A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)"

[13/03/2024 – Current]

Subinvestigator in phase II PE-PE trial (NCT05578664)

"Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer (PE-PE)"

[03/2024 – Current]

Subinvestigator in BRIDGE study

"A prospective observational cohort study to evaluate miRNA 371 and outcomes in patients with newly diagnosed germ cell tumors" (protocol number: 023-FPO21)".

[09/2024 – Current]

Subinvestigator in SPECTRE study

[10/2024 – Current]

Subinvestigator in EVIDENCE study

ABSTRACT

[2022]

"D13. A hypothesis generating analysis on the Role Of Tert Promoter Mutation In Advanced Urothelial Carcinoma Treated With Immunotherapy."

Marchese P.V., Mollica V., De Biase D., Giunchi F., Nuvola G., Marchetti A., **Rosellini M.**, Tassinari E., Fiorentino M., Massari F. *XXIV National Congress AIOM, Rome, 01-03 Oct 2022*

[2022]

"Multidisciplinary Unit for the Management of Urothelial Carcinoma"

Mollica V., Chessa F., Massari F., Nuvola G., Marchetti A., **Rosellini M.**, Tassinari E., Schiavina R., Brunocilla E. *XXXII National Congress SIUrO, Florence, 6-8 Oct 2022*

Abstract 43

[2022]

"A hypothesis generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy"

Marchese P.V., Mollica V., De Biase D., Giunchi F., Nuvola G., Marchetti A., **Rosellini M.**, Tassinari E., Fiorentino M., Massari F. *XXXII National Congress SIUrO, Florence, 6-8 Oct 2022*

Oral presentation at "Presidential Symposium" (abstract 41)

[2023]

"P153. A hypothesis generating analysis of the role of chromosome 3p-related genes as predictors for immunocombinations in metastatic renal cell carcinoma (mRCC)"

Rosellini M., Mollica V., Coluccelli S., Giunchi F., Ricci C., Marchetti A., Tassinari E., Fiorentino M., De Biase D., Massari F.

European Urology Open Science 2023;57(Supplement 1): S222

The 15th European Multidisciplinary Congress on Urological Cancers 2023 (EMUC23), Marseille, 2-5 Nov 2023

Link: [https://doi.org/10.1016/S2666-1683\(23\)01448-9](https://doi.org/10.1016/S2666-1683(23)01448-9)

[2023]

"A19. Telomerase reverse transcriptase promoter (TERTp) mutations as potential biomarker in patients (pts) with advanced urothelial carcinoma (aUC)."

Tassinari E., Mollica V., Giunchi F., Marchese P.V., Maloberto T., Tateo V., Ricci C., **Rosellini M.**, Marchetti A., Fiorentino M., De Biase D., Massari F. *XXV Congresso Nazionale AIOM, Rome, 10-12 Nov 2023.*

[2023]

"A36. A prospective study on the utility of PET/CT in the early evaluation of response to androgen receptor targeted agents (ARTA) in metastatic castration-resistant prostate cancer (mCRPC)."

Marchetti A., Mollica V., **Rosellini M.**, Tassinari E., Tabacchi E., Paccapelo A., Tateo V., Fanti S., Massari F. *XXV Congresso Nazionale AIOM, Rome, 10-12 Nov 2023*

[2023]

"A46. Evaluation of response to pembrolizumab plus axitinib with tumor growth rate (TGR) in patients (pts) with metastatic renal cell carcinoma (mRCC)",

Rosellini M., Mollica V., Brocchi S., Galuppi F., Paccapelo A., Marchetti A., Tassinari E., Tateo V., Santoni M., Massari F. *XXV Congresso Nazionale AIOM, Rome, 10-12 Nov 2023*

[2023]

"24P. Chromosome 3p-related gene alterations (GA) as biomarkers for immunocombinations in metastatic renal cell carcinoma (mRCC): a hypothesis-generating analysis"

Rosellini M., Mollica V., Coluccelli S., Giunchi F., Ricci C., Marchetti A., Tassinari E., Fiorentino M., De Biase D., Massari F. *Annals of Oncology* (2023) 20 (suppl_1): 100412-100412.

ESMO Immuno-Oncology Congress 2023, 6-8 Dec 2023

Link: [10.1016/j.iontech.2023.100493](https://doi.org/10.1016/j.iontech.2023.100493)

MEMBERSHIP

[06/2023 – Current]

AIOM Member

Associazione Italiana di Oncologia Medica

[10/2023 – Current]

ESMO Member

European Society of Medical Oncology

ORCHID

ORCHID: 0000-0002-4920-9951

Si autorizza al trattamento dei dati personali presenti in tale C.V. secondo quanto indicato dal Decreto Legislativo 196/2003 e successivo aggiornamento con D.Lgs 101/2018, nonché ai sensi del GDPR 679/2016.